Payment overview · 2025
General Payments
$572.22
29 reported records · 14 companies
Healthcare provider profile · identity verified
David J Lozowski, DO
Allopathic & Osteopathic Physicians|Family Medicine · COSHOCTON, OH · NPI 1588669543
Verified facts
What the public records show
CMS Open Payments records show David J Lozowski, DO received $572.22 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.94 | 30.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.80 | 14.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.14 | 7.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.52 | 7.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.94 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.25 | 5.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.69 | 4.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.80 | 4.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.67 | 4.1% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $22.12 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.57 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.48 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.21 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.09 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $572.22 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.38 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.67 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.93 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.14 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 105 |
| Lisinopril | Lisinopril | 284 | 95 |
| Atenolol | Atenolol | 255 | 78 |
| Gabapentin | Gabapentin | 229 | 64 |
| Omeprazole | Omeprazole | 220 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 62 |
| Furosemide | Furosemide | 178 | 66 |
| Metformin Hcl | Metformin Hcl | 162 | 56 |
| Potassium Chloride | Potassium Chloride | 157 | 49 |
| Simvastatin | Simvastatin | 149 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 48 |
| Losartan Potassium | Losartan Potassium | 142 | 54 |
| Eliquis | Apixaban | 139 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 50 |
| Meloxicam | Meloxicam | 116 | 46 |
| Prednisone | Prednisone | 112 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 43 |
| Glipizide | Glipizide | 101 | 33 |
| Carvedilol | Carvedilol | 95 | 31 |
| Sertraline Hcl | Sertraline Hcl | 94 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 29 |
| Farxiga | Dapagliflozin Propanediol | 82 | 19 |
| Tramadol Hcl | Tramadol Hcl | 72 | 33 |
| Famotidine | Famotidine | 69 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 19 |
| Glimepiride | Glimepiride | 60 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 15 |
| Allopurinol | Allopurinol | 57 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 19 |
| Trazodone Hcl | Trazodone Hcl | 53 | 17 |
| Finasteride | Finasteride | 51 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Xarelto | Rivaroxaban | 51 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 14 |
| Alprazolam | Alprazolam | 48 | 14 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 13 |
| Metformin Hcl Er | Metformin Hcl | 45 | 21 |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Azithromycin | Azithromycin | 41 | 36 |
| Cefdinir | Cefdinir | 41 | 39 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 12 |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 14 |
| Spironolactone | Spironolactone | 29 | 11 |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Primidone | Primidone | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 15 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $572.22 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CHARTIS CATHETER, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GVOKE HYPOPEN, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, PULMONX CHARTIS TABLET CONSOLE, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, TRUMENBA, VOQUEZNA, VRAYLAR, Wegovy, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error